References
- Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14. https://doi.org/10.1016/S0140-6736(05)67530-7
- Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230:663-71. https://doi.org/10.1097/00000658-199911000-00008
- Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57. https://doi.org/10.1097/00000658-199709000-00004
- Edge SB; American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
- Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-700. https://doi.org/10.1002/cncr.11699
- Park JH, Choi EK, Ahn SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2011;79:696-704. https://doi.org/10.1016/j.ijrobp.2009.12.031
- Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2010;78:194-8. https://doi.org/10.1016/j.ijrobp.2009.07.003
- Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178-82. https://doi.org/10.1016/j.ijrobp.2006.11.048
- Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999;44:121-6. https://doi.org/10.1016/S0360-3016(98)00509-4
- Morganti AG, Trodella L, Valentini V, et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000;46:913-9. https://doi.org/10.1016/S0360-3016(99)00487-3
- Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22. https://doi.org/10.1200/JCO.2008.18.6288
- Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 2011;81:e853-9. https://doi.org/10.1016/j.ijrobp.2010.12.019
- He P, Shi JS, Chen WK, Wang ZR, Ren H, Li H. Multivariate statistical analysis of clinicopathologic factors influencing survival of patients with bile duct carcinoma. World J Gastroenterol 2002;8:943-6. https://doi.org/10.3748/wjg.v8.i5.943
- Nagakawa T, Mori K, Nakano T, et al. Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 1993;80: 619-21. https://doi.org/10.1002/bjs.1800800526
- Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384-94. https://doi.org/10.1097/00000658-199604000-00007
- Nakagohri T, Asano T, Kinoshita H, et al. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 2003;27:289-93. https://doi.org/10.1007/s00268-002-6696-7
- Harrison LB, Sessions RB, Hong WK. Head and neck cancer: a multidisciplinary approach. 3rd ed. Philadelphia, PA: Lipppincott Williams & Wilkins; 2009.
- Koh HK, Park HJ, Kim K, Chie EK, Min HS, Ha SW. Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery. Radiat Oncol J 2012;30:197-204. https://doi.org/10.3857/roj.2012.30.4.197
- Im JH, Seong J, Lee J, et al. Postoperative radiotherapy dose correlates with locoregional control in patients with extrahepatic bile duct cancer. Radiat Oncol J 2014;32:7-13. https://doi.org/10.3857/roj.2014.32.1.7
- Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788-97. https://doi.org/10.1097/00000658-199506000-00017
Cited by
- Surgery Alone Versus Surgery Followed by Chemotherapy and Radiotherapy in Resected Extrahepatic Bile Duct Cancer: Treatment Outcome Analysis of 336 Patients vol.48, pp.2, 2014, https://doi.org/10.4143/crt.2015.091
- Postoperative radiotherapy appeared to improve the disease free survival rate of patients with extrahepatic bile duct cancer at high risk of loco-regional recurrence vol.34, pp.4, 2014, https://doi.org/10.3857/roj.2016.01879
- Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer vol.79, pp.6, 2014, https://doi.org/10.1007/s00280-017-3312-y
- Predictive factors of gastroduodenal bleeding after postoperative radiotherapy in biliary tract cancer vol.47, pp.4, 2014, https://doi.org/10.1093/jjco/hyw205
- Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution vol.49, pp.2, 2017, https://doi.org/10.4143/crt.2016.166
- Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer vol.103, pp.4, 2014, https://doi.org/10.5301/tj.5000666
- Prognostic value of carbohydrate antigen 19‐9 in patients undergoing resection of biliary tract cancer vol.104, pp.3, 2014, https://doi.org/10.1002/bjs.10415
- Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery vol.90, pp.1080, 2017, https://doi.org/10.1259/bjr.20170308
- The impact of perioperative CA19‐9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma vol.117, pp.3, 2014, https://doi.org/10.1002/jso.24856
- High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients vol.44, pp.5, 2014, https://doi.org/10.1016/j.ejso.2018.01.012
- Risk factors associated with locoregional failure and estimation of survival after curative resection for patients with distal bile duct cancer vol.9, pp.None, 2014, https://doi.org/10.1038/s41598-019-41622-2
- Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for “Borderline Resectable” in the Field of Surgery for Hilar Cholangiocarcinoma vol.43, pp.4, 2014, https://doi.org/10.1007/s00268-018-04883-y
- Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives vol.7, pp.11, 2019, https://doi.org/10.12998/wjcc.v7.i11.1242
- Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer vol.37, pp.4, 2019, https://doi.org/10.3857/roj.2019.00430
- Utility of Endoscopic Ultrasound-Guided Fine Needle Aspiration in the Diagnosis of Local Recurrence of Pancreaticobiliary Cancer after Surgical Resection vol.14, pp.5, 2014, https://doi.org/10.5009/gnl19200
- Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma vol.10, pp.7, 2014, https://doi.org/10.3390/jcm10071345